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Factor Replacement

Introduction3,5
Hemophilia refers to an inherited
bleeding disorder caused by deficiency of
coagulation factor VIII (hemophilia A),
factor IX (hemophilia B), or factor XI
(hemophilia C). Hemophilia A and B are
X-linked recessive diseases that present
in male children of carrier females.3,4

Purified factor products are the 1st choice and
should be used whenever possible to avoid
potential transfusion-transmitted infection and
transfusion reactions.2,4
However, other blood products like
Cryoprecipitate can also be used. One bag of
Cryoprecipitate is made from approximately 250
mL of fresh frozen plasma (FFP) and contains
approximately 70 to 80 units of factor VIII in a
volume of 30 to 40 mL (approximately 3 to 5
units/mL).2

Hemophilia A – Inherited deficiency of
factor VIII; an X-linked recessive
disorder4.

Case description
Patient is a 5-year-old male with severe
factor VIII deficiency initially diagnosed, at
age 3, as severe oral bleeding following a
lip laceration. His factor VIII was less
than 1%. Consequently, patient had been
on "on demand" replacement but, due to
an increase in bleeds, is being switched
to prophylaxis. The main joints affected
are the elbows, knees and ankles.
Because of the increasing need for home
factor infusion, a Port-A-Cath is being
placed.
His disease is considered
severe.
The known duration is
approximately
two
years
and
is
associated
with
spontaneous
hemarthroses and bleeding.
It is
ameliorated with factor replacement.
Patient is to receive Recombinant factor
VIII 500 units IV twice a week
(approximately 18 U/kg).
Before the procedure, patient received
approximately 50 U/kg of recombinant
factor VIII immediately before the port
placement. He was intubated with an
LMA and had no excessive bleeding
during the procedure.

Fig. 1. Source: Bhat R, Cabey
W. Evaluation and
Management of Congenital
Bleeding Disorders.6
Downloaded from Clinical
Key. Accessed Sept 22, 2018.

Fig. 2. Source: Managing Your
Hemophilia.. Copy right ©
2016 by Saunders, an imprint of
Elsevier, Inc. Downloaded from
ClinicalKey. Accessed Sept. 22,
2018.

FFP is deemed an inadequate choice for factor
replacement because 1mL of FFP contains 1unit
of factor activity. A dose of 15 to 20 mL/kg will
raise the factor VIII level by approximately 30 to 40
percent. This amounts to lots of bags of FFP to
get the desired factor amount, which
consequently exposes patient to possible fluid
overload, transfusion infections and reactions.1,2

Therapies other than factor replacement 1,2,4

Therapies
Tranexamic Acid
(TXA)

Epsilon
Aminocaproic
Acid (EACA)
Desmopressin
(DDAVP)

1.
2.
3.
4.
5.
6.

Use
Inhibit fibrinolysis by inhibiting
plasminogen activation in the
fibrin clot, thereby enhancing
clot stability.
Same as above

Increases factor VIII level twofour fold. Not effective for
patients with severe
hemophilia A (Factor VIII
activity <1%).

DOSAGES
25 mg/kg every 6-8 hours

75-100 mg/kg every 6 hours, max 3-4g

0.3 mcg/kg (max, 20 mcg/kg), IV or nasal
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Discussion
Hemophilia A (factor VIII deficiency) is an X-linked coagulation factor
disorder associated with bleeding of variable severity, from life-threatening
to clinically silent. 1
Factor VIII deficiency/Hemophilia A affects 1 in 5000 to 10,000 males;
roughly 60 percent have severe disease, with factor VIII activity less than
1 percent of normal.1,2
The factor VIII gene is located on the X chromosome. It is one of the
largest known genes. It circulates in plasma with von Willebrand factor.
Cleavage of factor VIII by thrombin or factor Xa is necessary to activate
factor VIII and allow it to participate in the intrinsic pathway. Activated
factor VIII is inactivated by activated protein C in conjunction with
proteins.3,4,5
In patients with hemophilia with acute bleeding, the immediate goal is to
raise the factor activity to a level sufficient to achieve hemostasis.2
For severe bleeding, the factor activity level should be maintained above
50 percent at all times.
An initial dose of 50 units/kg to raise the factor VIII level to 100 percent
should be given. The second and subsequent doses are given at intervals
of approximately one half-life of the infused product for that patient. A
typical half-life for standard half-life factor VIII products is approximately 8
to 12 hours.2,3
For patients who require perioperative factor administration, the initial
dose should be timed to provide maximal coverage at the time of greatest
bleeding risk (or, typically, 30 to 60 minutes before the procedure). The
dose is calculated from the patient's weight, baseline factor level, desired
factor level, volume of distribution, and presence of an inhibitor.2,5

Conclusion
• Perioperative management of Factor VIII deficiency, is dependent on
the severity of the factor deficiency as well as the type of procedure
being performed.1,3
• Factor VIII replacement with recombinant Factor VIII, 30 minutes
before surgery, is the preferred method of treatment; however,
alternative forms of replacement, factor related and otherwise, can be
implemented.2,4
• Depending on the surgery, factor replacement should be given before
and after surgery, as surgeries with a lot of blood loss deplete Factor
VIII faster.2,3,5

